GLP-1 Drugs: Stopping Is Often Temporary
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
GLP-1 Drugs: Stopping Is Often Temporary
-
ナレーター：
-
著者：
New research reveals that most people who stop GLP-1 meds like Ozempic for type 2 diabetes don’t quit for good—they often return within a year. Over half restart within a year, and nearly two-thirds within two, showing these drugs remain vital even with treatment breaks. Discontinuation is more common among Medicaid/Medicare patients, Black individuals, and those with nausea, but patients seen by endocrinologists are more likely to stick with therapy. Newer drugs like tirzepatide and semaglutide show better persistence, highlighting the importance of consistent use to prevent heart and kidney complications. This insight can help providers and policymakers better support patients through the full benefits of these life-changing treatments.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/9391f17a9ada3bd0